/BTG/media/Main/Slider/slide_6.png?ext=.png

UTILITY BEYOND VISIBILITY

VISION > PRECISION > ASSURANCE

/BTG/media/Main/Slider/Slide_1.jpg?ext=.jpg

a new level of control

The next-generation development of the gold-standard DC Bead™ has landed

/BTG/media/Main/Slider/slide_2.jpg?ext=.jpg

a new level of control

DC Bead LUMI™ offers lasting radiopacity combined with CE Mark approved indication for drug loading

SEE MORE TREAT SMARTER

CBT ≤ 90 mins post LUMI-TACE

This case was impressive because of the clear visualisation of the tumour and the embolised vessels on the post-embolisation non-contrast CBCT, in addition to the complete response of the related lesions.

CBT 10 mins post LUMI-TACE

After 4 weeks of follow-up, a complete response on mRECIST was demonstrated with a decrease in tumour size to 0.9 mm.

CT post LUMI-TACE

The radiopaque property of DC Bead LUMI™ allows for accurate needle placement and full lesion ablation. If the lesion cannot be seen on non-contrast CT, there is a possibility that the lesion may not be fully ablated.

DC Bead Lumi KOL

 
Building on the established clinical performance of DC Bead®, DC Bead LUMI™ comprises a radiopaque moiety1, allowing for a more precisely controlled procedure and the opportunity to revolutionize the treatment of hypervascular tumors and arteriovenous malformations (AVMs).
Find out more

Register for updates

Click Here

EVENTS

24 Feb APCCVIR

11 Apr ECIO

12 May GEST

All Events

CORPORATE AND REGIONAL PRESS RELEASES

14 Feb A Retrospective Study of Medicare claim ...

03 Dec Arizona Patients Successfully Receive th...

20 Nov Recommended Cash Offer for BTG plc by Bo...

All Press Releases

Information Information

NOTEWORTHY NEWS

28 Apr OPTALYSE PE Results Presented at Society...

25 Aug Health Canada approves radiopaque bead f...

17 May Healthcare Player BTG on lookout for acq...

All News

Information Information

About BTG

About Interventional Oncology

Interventional Oncology Products

Imagine where we can go.

Important Safety Information:


INDICATION:

DC Bead LUMI™ can be used as an embolic agent with or without delivery of doxorubicin or irinotecan. Unloaded DC Bead LUMI™ are intended to be used for the embolisation of non-malignant hypervascular tumours and arteriovenous malformations (AVMs).

For the use in malignant indications:

  • DC Bead LUMI™ are primarily intended as an embolic agent for the local treatment of malignant hypervascularised tumour(s) in the liver.
  • DC Bead LUMI™ are compatible with doxorubicin for the local treatment of tumours in patients with hepatocellular carcinoma (HCC). Doxorubicin can be loaded prior to embolisation and then as a secondary action, the beads will elute a local, controlled and sustained dose to the tumour after embolisation.
  • DC Bead LUMI™ are also intended to embolise the vessels supplying malignant colorectal cancer metastasised to the liver (mCRC).
  • DC Bead LUMI™ are compatible with irinotecan which can be loaded prior to embolisation and then as a secondary action, the beads will elute a local, controlled and sustained dose to the liver metastases from colorectal cancer after embolisation.

WARNING:

It is the doctor’s responsibility to give due consideration to the details in the drug product marketing authorisation in deciding which drug (either doxorubicin or irinotecan) to load DC Bead LUMI™ with and whether loading with that drug is appropriate for the patient under his/her care .The relevant Summary of Product Characteristics (SmPC) must be consulted. The type and dose of drug should also be assessed according to the individual patient’s clinical circumstances.

DC Bead and DC Bead LUMI are trademarks and/or registered trademarks of Biocompatibles UK Limited, a BTG International group company. Imagine where we can go, BTG and the BTG roundel logo are trademarks of BTG International Ltd. BTG and the BTG roundel logo are registered trademarks in the USA, the European Union and certain other territories. © 2017 Biocompatibles UK Ltd. EM-LUM-2017-0025. EMEA. Date of preparation January 2017.